专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明专利

JP2008119005A Method for measuring telomere length 审中-公开
标题翻译：测量TELOMERE LENGTH的方法
公开(公告)号：JP2008119005A
公开(公告)日：2008-05-29
申请号：JP2007329366
申请日：2007-12-20
申请人： Geron Corp , ジェロン・コーポレーションGeron Corporation
发明人： KOZLOWSKI MICHAEL R , PROWSE KAREN R , WANG SY-SHI , WONG SHARON , KIM NAM WOO
IPC分类号： C12Q1/68 , G01N27/447 , C12N15/09
CPC分类号： C12Q1/6816 , C12Q2565/518 , C12Q2521/301
摘要： PROBLEM TO BE SOLVED: To provide a more rapid, reliable, accurate and efficient method for measuring telomere length. SOLUTION: The method for measuring telomere length comprises the step (a) which allows an oligonucleotide linker to be covalently connected to a telomere having a desired length, the step (b) which allows the linker to sufficiently contact with a primer including the complementary sequence to specifically cause hybridization with this linker by elongating the primer under the condition that can generate the complementary primer elongated product, and the step (c) which allows the telomere length to be related with the size of the primer elongated product, thereby providing the standard scale of the telomere length. COPYRIGHT: (C)2008,JPO&INPIT
摘要翻译：要解决的问题：为了提供更快速，可靠，准确和有效的测量端粒长度的方法。解决方案：测量端粒长度的方法包括步骤（a），其允许寡核苷酸接头共价连接到具有所需长度的端粒，步骤（b）允许接头与引物充分接触，包括通过在可以产生互补引物长度产物的条件下拉伸引物，并且允许端粒长度与引物细长产品的尺寸相关的步骤（c），特异性引发与该接头的杂交的互补序列，从而提供端粒长度的标准规模。版权所有（C）2008，JPO＆INPIT

32. 发明专利

JP2001072592A TELOMERASE INHIBITOR 失效
公开(公告)号：JP2001072592A
公开(公告)日：2001-03-21
申请号：JP30757699
申请日：1999-10-28
申请人： KYOWA HAKKO KOGYO KK , GERON CORP
发明人： AKAMA TSUTOMU , ASAI AKIYOSHI , KANDA YUTAKA , YAMASHITA NOBUNORI
IPC分类号： C07D277/20 , A61K31/426 , A61K31/427 , A61K31/4439 , A61K31/506 , A61P35/00 , A61P43/00 , C07D277/34 , C07D277/36 , C07D417/06 , C07D417/10 , C07D513/04
摘要： PROBLEM TO BE SOLVED: To obtain a telomerase inhibitor useful for treating diseases associated with telomerase activity including malignant tumors by including a compound having a specific thiazoline skeleton and exhibiting a telomerase inhibition activity. SOLUTION: This inhibitor contains a compound having a 2,4-dioxothiazoline skeleton or 4-oxo-2-thiothiazoline skeleton, and exhibiting telomerase inhibitor activity as an active ingredient. The compound is preferably a compound of the formula [R is a (substituted) aryl, a (substituted) heteroaryl, a (substituted) aryalkyl or the like; Q1 is O or S; Q2 and Q3 are each H, a (substituted) arylsulfonyl or a (substituted) heteroarylsulfonyl, or they together form a bond, or the like; Q4 is H or a (substituted) lower alkyl] or its pharmaceutically permissible salt. The effective dose and adiministration frequency of the compound of the formula depend on administration form and others, but commonly 0.01-20 mg/kg a day is preferably administered in a 1-4 divided doses.

33. 发明专利

JPH1149676A PYRIDINE-BASED TELOMERASE INHIBITOR 失效
公开(公告)号：JPH1149676A
公开(公告)日：1999-02-23
申请号：JP20584797
申请日：1997-07-31
申请人： GERON CORP
发明人： FEDERICO GAETA , ELAINE STRACKER
IPC分类号： C07D213/85 , A61K31/33 , A61K31/44 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： PROBLEM TO BE SOLVED: To obtain a new pyridine-based compound useful as a medicine inhibiting a human.telomerase as a ribonucleic protein enzyme relating to human.telomere DNA synthesis and telomerase activity. SOLUTION: This pyridine-based telomerase inhibitor is a compound expressed by formula I [X1 is O or S; R1 is Yn R6 (n) is 0-10; when (n)&Egr;0, Y is methylene, etc.; R6 is an alkyl or the like}; R2 is H, an alkyl, cyano or the like; R3 and R4 are each H, amino, an alkylamino or the like; R5 is an alkyl iminyl, a phenyl iminyl or the like.] or its pharmacologically permissible salt, e.g. a compound of formula II in which X1 is S, R2 is cyano, R3 and R4 are each H, R5 is 3-methyl-2-pyridyliminyl and L is ethylene. The compound of the formula I is obtained by, for instance, transforming 2-thio-3- cyano-6-(dimethoxymethyl)pyridine to 2-thioether with an alkylation agent in the presence of a base and removing an acetal group to give an aldehyde compound, then reacting with an amine or a hydrazine derivative.

34. 发明专利

JP2014158490A Modified oligonucleotides for telomerase inhibition 审中-公开
标题翻译：修饰的寡核苷酸用于TELOMERASE抑制
公开(公告)号：JP2014158490A
公开(公告)日：2014-09-04
申请号：JP2014087190
申请日：2014-04-21
申请人： Geron Corp , ジェロン・コーポレーションGeron Corporation
发明人： GRYAZNOV SERGEI , PONGRACZ KRISZTINA
IPC分类号： C12N15/09 , A01N43/04 , A61K31/7088 , A61K48/00 , A61P35/00 , A61P43/00 , C07H21/02 , C07H21/04 , C12N20060101 , C12N5/00 , C12N9/99 , C12N15/113
CPC分类号： C12N15/115 , A61K47/48038 , A61K47/48046 , A61K47/48053 , A61K47/48123 , A61K47/542 , A61K47/543 , A61K47/544 , A61K47/554 , C07C233/18 , C07H21/02 , C07H21/04 , C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/113 , C12N2310/14 , C12N2310/31 , C12N2310/314 , C12N2310/351 , C12N2310/3515 , C12N2320/30 , C12Y207/07049
摘要： PROBLEM TO BE SOLVED: To provide modified oligonucleotides for telomerase inhibition.SOLUTION: Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics. This means that an equivalent biological effect may be obtained using smaller amounts of the conjugated oligonucleotide compared to the unmodified form. The compositions and methods of the invention relate to telomerase inhibiting compounds comprising an oligonucleotide and at least one covalently linked lipid group.
摘要翻译：要解决的问题：提供用于端粒酶抑制的修饰的寡核苷酸。解决方案：公开了包含与脂质部分共价连接的寡核苷酸部分的化合物。寡核苷酸部分包含与人端粒酶的RNA成分互补的序列。该化合物在高效能细胞中抑制端粒酶活性并具有优异的细胞摄取特征。这意味着与未修饰形式相比，可以使用较少量的缀合的寡核苷酸获得等效的生物学效应。本发明的组合物和方法涉及包含寡核苷酸和至少一种共价连接的脂质基团的端粒酶抑制化合物。

35. 发明专利

JP2012205592A Hepatocyte lineage cell derived from pluripotent stem cell 有权
标题翻译：来自PLUIPOTENT STEM CELL的HEPATOCYTE线粒体细胞
公开(公告)号：JP2012205592A
公开(公告)日：2012-10-25
申请号：JP2012139735
申请日：2012-06-21
申请人： Geron Corp , ジェロン・コーポレーションGeron Corporation
发明人： RAMBHATLA LAKSHMI , CARPENTER MELISSA K
IPC分类号： C12N5/0735 , C12N15/09 , A61L27/00 , A61P1/16 , C12N5/02 , C12N5/071 , C12N5/10 , C12Q1/02
CPC分类号： C12N5/067 , C12N2500/30 , C12N2500/36 , C12N2501/11 , C12N2501/115 , C12N2501/12 , C12N2501/148 , C12N2501/33 , C12N2501/335 , C12N2501/385 , C12N2501/39 , C12N2503/02 , C12N2506/02 , C12N2533/90
摘要： PROBLEM TO BE SOLVED: To provide technology to generate more homogeneous differentiated cell populations from pluripotent embryonic cells of primate origin, particularly those from humans.SOLUTION: It is discovered that when pluripotent stem cells are cultured in the presence of a hepatocyte differentiation inducer, a population of cells is derived that has a remarkably high proportion of cells with phenotypic characteristics of liver cells. In one example, human embryonic stem cells are allowed to form embryoid bodies, and then combined with the differentiation inducer n-butyric acid, optionally supplemented with maturation factors. In another example, n-butyric acid is added to human embryonic stem cells in feeder-free culture. Either way, a remarkably uniform cell population is obtained, which is predominated by cells with morphological features of hepatocytes, expressing surface markers characteristic of hepatocytes, and having enzymatic and biosynthetic activity important for liver function. Since stem cells readily proliferate in culture, this system provides an abundant source of cells of the hepatocyte lineage for a variety of applications, such as drug screening, and restoring liver function in the context of clinical treatment.
摘要翻译：要解决的问题：提供技术以从灵长类来源的多能胚胎细胞，特别是来自人类的多能胚胎细胞产生更均匀的分化细胞群体。解决方案：发现当多能干细胞在肝细胞分化诱导物存在时培养时，得到的细胞群具有非常高比例的具有肝细胞表型特征的细胞。在一个实例中，允许人胚胎干细胞形成胚状体，然后与分化诱导剂正丁酸组合，任选地补充成熟因子。在另一个实例中，在无饲料培养中将正丁酸加入到人胚胎干细胞中。无论哪种方式，获得了显着均匀的细胞群，其由具有肝细胞形态特征的细胞占主导，表达肝细胞特征的表达标志物，并具有对肝功能重要的酶和生物合成活性。由于干细胞在培养物中容易增殖，所以该系统为临床治疗的各种应用提供了丰富的肝细胞谱系细胞来源，例如药物筛选和恢复肝功能。版权所有（C）2013，JPO＆INPIT

36. 发明专利

JP2012085648A Modified oligonucleotide for telomerase inhibition 审中-公开
标题翻译：修饰的寡核苷酸用于TELOMERASE抑制
公开(公告)号：JP2012085648A
公开(公告)日：2012-05-10
申请号：JP2011274595
申请日：2011-12-15
申请人： Geron Corp , ジェロン・コーポレーションGeron Corporation
发明人： GRYAZNOV SERGEI , PONGRACZ KRISZTINA
IPC分类号： C12N15/115 , A01N43/04 , A61K31/7105 , A61K31/7125 , A61K47/48 , A61K48/00 , A61P35/00 , A61P35/02 , A61P43/00 , C07H21/02 , C07H21/04 , C12N20060101 , C12N5/00 , C12N9/99 , C12N15/113
CPC分类号： C12N15/115 , A61K47/48038 , A61K47/48046 , A61K47/48053 , A61K47/48123 , A61K47/542 , A61K47/543 , A61K47/544 , A61K47/554 , C07C233/18 , C07H21/02 , C07H21/04 , C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/113 , C12N2310/14 , C12N2310/31 , C12N2310/314 , C12N2310/351 , C12N2310/3515 , C12N2320/30 , C12Y207/07049
摘要： PROBLEM TO BE SOLVED: To provide modified oligonucleotides for telomerase inhibition.SOLUTION: Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics. This means that an equivalent biological effect may be obtained using smaller amounts of the conjugated oligonucleotide compared to an unmodified form. The compositions and methods relate to telomerase inhibiting compounds comprising an oligonucleotide and at least one covalently linked lipid group.
摘要翻译：待解决的问题：提供修饰的寡核苷酸用于端粒酶抑制。公开了包含与脂质部分共价连接的寡核苷酸部分的化合物。寡核苷酸部分包含与人端粒酶的RNA成分互补的序列。该化合物在高效能细胞中抑制端粒酶活性并具有优异的细胞摄取特征。这意味着与未改性形式相比，可以使用较少量的缀合的寡核苷酸获得等效的生物效应。组合物和方法涉及包含寡核苷酸和至少一个共价连接的脂质组的端粒末端抑制化合物。版权所有（C）2012，JPO＆INPIT

37. 发明专利

JP2011050385A Cell of cardiomyocyte lineage produced from human pluripotent stem cell 有权
标题翻译：由人类细胞干细胞产生的心脏细胞系细胞
公开(公告)号：JP2011050385A
公开(公告)日：2011-03-17
申请号：JP2010219095
申请日：2010-09-29
申请人： Geron Corp , ジェロン・コーポレーションGeron Corporation
发明人： XU CHUNHUI
IPC分类号： C12N5/0735 , C12N15/09 , A61K35/28 , A61K35/34 , A61K35/54 , A61P9/00 , A61P9/10 , C12N5/02 , C12N5/077 , C12N5/10 , C12Q1/02
CPC分类号： C12N5/0657 , A61K35/12 , C12N5/0606 , C12N2500/30 , C12N2500/44 , C12N2500/62 , C12N2501/06 , C12N2501/105 , C12N2501/15 , C12N2501/155 , C12N2501/385 , C12N2501/999 , C12N2503/02 , C12N2506/02 , C12N2510/00
摘要： PROBLEM TO BE SOLVED: To provides human cell populations of the cardiomyocyte lineage. SOLUTION: The cells are obtained by causing cultures of pluripotent stem cells to differentiate in vitro, and then harvesting cells with certain phenotypic features. Differentiated cells bear cell surface and morphologic markers characteristic of cardiomyocytes, and a proportion of them undergo spontaneous periodic contraction. Highly enriched populations of cardiomyocytes and their replicating precursor cells, suitable for a variety of applications, such as drug screening and therapy for cardiac disease, can be obtained. COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译：要解决的问题：提供心肌细胞谱系的人类细胞群体。解决方案：通过使多能干细胞的培养物在体外分化获得细胞，然后收获具有某些表型特征的细胞。分化细胞具有心肌细胞特征的细胞表面和形态学标记，其中一部分经历自发性周期性收缩。可以获得适合各种应用的心肌细胞及其复制前体细胞的高度富集的群体，例如用于心脏病的药物筛选和治疗。版权所有（C）2011，JPO＆INPIT

38. 发明专利

JP2001081042A HUMAN TELOMERASE-CATALYTIC SUBUNIT 失效
公开(公告)号：JP2001081042A
公开(公告)日：2001-03-27
申请号：JP2000227474
申请日：2000-07-27
申请人： GERON CORP , UNIV TECHNOLOGY CORP
发明人： CECH THOMAS R , LINGNER JOACHIM , NAKAMURA TORU , CHAPMAN KAREN B , MORIN GREGG B , HARLEY CALVIN B , ANDREWS WILLIAM H
IPC分类号： A01K67/027 , A61K31/70 , A61K31/7088 , A61K35/12 , A61K38/00 , A61K38/45 , A61K38/55 , A61K39/00 , A61K39/395 , A61K48/00 , A61P35/00 , A61P43/00 , C07K5/10 , C07K5/107 , C07K5/117 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/40 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/12 , C12N15/09 , C12N15/113 , C12N15/12 , C12N15/54 , C12N15/85 , C12P21/08 , C12Q1/02 , C12Q1/48 , C12Q1/68 , C12R1/19 , C12R1/84 , C12R1/91 , G01N33/15 , G01N33/48 , G01N33/50 , G01N33/53 , G01N33/566 , G01N33/573
摘要： PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition capable of blocking the effect of senility or cancer by including a pharmaceutically acceptable carrier and a specific molecule. SOLUTION: This composition contains (A) a pharmaceutically acceptable carrier and (B) an hTRT polypeptide encoded by a TRT polynucleotide containing a sequence encoding a polypeptide capable of exhibiting a telomerase catalytic activities when being associated with a telomerase RNA, such as (i) a polynucleotide having a sequence of an insert of plasmid ATCC 209016, (ii) a polynucleotide hybridizing with a polynucleotide complementary to the component (i) under a stringent condition, (iii) a polynucleotide hybridizing with a polynucleotide complementary to a base sequence of the formula, or (iv) a polynucleotide being in a degeneration state as a result of a genetic cord to the components (i) or (ii), or a molecule of a recombinant hTRT antibody (fragment) or the like.

39. 发明专利

JPH11313689A HUMAN TELOMERASE CATALYTIC SUBUNIT 失效
公开(公告)号：JPH11313689A
公开(公告)日：1999-11-16
申请号：JP4241099
申请日：1999-02-19
申请人： GERON CORP , UNIV TECHNOLOGY CORP
发明人： CECH THOMAS R , LINGNER JOACHIM , NAKAMURA TORU , CHAPMAN KAREN B , MORIN GREGG B , HARLEY CALVIN B , ANDREWS WILLIAM H
IPC分类号： A01K67/027 , A61K31/70 , A61K31/7088 , A61K35/12 , A61K38/00 , A61K38/45 , A61K38/55 , A61K39/00 , A61K39/395 , A61K48/00 , A61P35/00 , A61P43/00 , C07K5/10 , C07K5/107 , C07K5/117 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/40 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/12 , C12N15/09 , C12N15/113 , C12N15/12 , C12N15/54 , C12N15/85 , C12P21/08 , C12Q1/02 , C12Q1/48 , C12Q1/68 , C12R1/19 , C12R1/84 , C12R1/91 , G01N33/15 , G01N33/48 , G01N33/50 , G01N33/53 , G01N33/566 , G01N33/573
摘要： PROBLEM TO BE SOLVED: To obtain a new polynucleotide containing a specific base sequence, encoding a polypeptide having at least one activity of a human telomerase reverse transcriptase protein, useful for diagnosis, prognosis, treatment, etc., of diseases such as cancer, etc. SOLUTION: This new polynucleotide comprises a polynucleotide encoding a polypeptide having at least one activity of human telomerase reverse transcriptase protein, a polynucleotide having a sequence of formula I to formula III, a polynucleotide of at least ten nucleotides which is hybridized with the polynucleotides and encodes a protein having at least one activity of the human telomerase reverse transcriptase protein or a polynucleotide which is degenerated to the sequence prescribed above at the result of a genetic code and encodes a protein having at least one activity of the human telomerase reverse transcriptase protein, etc., has a changing action on the proliferating ability of cell and organism and is useful for diagnosis, prognosis, treatment, etc., of diseases such as cancer.

40. 发明专利

JPH10234384A HUMAN TELOMERASE CATALYTIC SUBUNIT 失效
公开(公告)号：JPH10234384A
公开(公告)日：1998-09-08
申请号：JP28618297
申请日：1997-10-01
申请人： GERON CORP , UNIV TECHNOLOGY CORP
发明人： CECH THOMAS R , LINGNER JOACHIM , NAKAMURA TORU , CHAPMAN KAREN B , MORIN GREGG B , HARLEY CALVIN B , ANDREWS WILLIAM H
IPC分类号： A01K67/027 , A61K31/70 , A61K31/7088 , A61K35/12 , A61K38/00 , A61K38/45 , A61K38/55 , A61K39/00 , A61K39/395 , A61K48/00 , A61P35/00 , A61P43/00 , C07K5/10 , C07K5/107 , C07K5/117 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/40 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/12 , C12N15/09 , C12N15/113 , C12N15/12 , C12N15/54 , C12N15/85 , C12P21/08 , C12Q1/02 , C12Q1/48 , C12Q1/68 , C12R1/19 , C12R1/84 , C12R1/91 , G01N33/15 , G01N33/48 , G01N33/50 , G01N33/53 , G01N33/566 , G01N33/573
摘要： PROBLEM TO BE SOLVED: To obtain the new subject catalytic protein-subunit comprising a human telomerase reverse transcriptase(hTRT) protein useful for changing proliferating ability of a cell or an organism, and for the diagnosis, aftercare, treatment, etc., of a disease such as a cancer. SOLUTION: A new protein comprising an isolated substantially pure preparation of a human telomerase reverse transcriptase(hTRT) protein having a sequence expressed by the formula, its varient or its fragment, or a recombinant protein preparation, etc. The new protein is useful for the diagnosis, aftercare and treatment of a human disease, for changing the proliferating ability of a cell or an organism, and for the identification, screening, etc., of a compound and a treatment, which are effective for curing a cancer, etc. This protein subunit is obtained by screening a human genome library prepared using DNAs isolated from WI38 pulmonary fibroblast by a probe and expressing the obtained hTRT gene in a host cell.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式